( Dec 2021)
| Bamlanivimab (LY-Co555) & Etesevimab (LY-CoV016) | ELI LILY (Pediatrics and NB) | Outpatient treatment, Post-exposure prophylaxis Effective against Delta variant |
| Casirivimab (REGN10933) & Imdevimab (REGN10987) | REGENERON (≥12 y and ≥40 kg) | Outpatient treatment, Post-exposure prophylaxis Effective against Delta variant |
| Sotrovimab (VIR-7831 ) | GSK (≥12 y and ≥40 kg) | Outpatient treatment, Post-exposure prophylaxis Effective against Omicron variant |
| Tixagevimab (AZD8895) & Cilgavimab (AZD1061) (AZD7442) (Evusheld) | ASTRAZENECA (≥12 y and ≥40 kg) Longer half life- 6 months | Pre-exposure prophylaxis, ( Immunocompromised or not eligible for vaccine.) Not authorised for treatment purpose. Can be REDOSED every 6 month. |
| Pre-exposure prophylaxis (tixagevimab/cilgavimab) |
| • Individuals who are NOT currently infected with SARS-CoV-2 and who have NOT had a known recent exposure to an individual infected with SARS-CoV-2 AND Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments AND may not mount an adequate immune response to COVID-19 vaccination OR For whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction (eg, severe allergic reaction) to a COVID-19 vaccine(s) and /or COVID-19 vaccine component(s). |
| Outpatient treatment (bamlanivimab/etesevimab, casirivimab/imdevimab, sotrovimab) |
| Individuals with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. |
| Post-exposure prophylaxis (bamlanivimab/etesevimab, casirivimab/imdevimab) |
| • Individuals who are at high risk for progressing to severe COVID-19, including hospitalization or death AND are not fully vaccinated OR not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination AND Who have been exposed to an individual infected with SARS-CoV-2 OR Who are at high risk of exposure to an individual infected with SARS-CoV-2 because of an occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting. |
Dr Ramakanta's Ideas 